NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03738397,A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis,https://clinicaltrials.gov/study/NCT03738397,Heads Up,COMPLETED,This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.,YES,Atopic Dermatitis,BIOLOGICAL: Upadacitinib|BIOLOGICAL: Dupilumab|DRUG: Placebo to dupilumab|DRUG: Placebo to upadacitinib,"Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease., Baseline and Week 16","Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 16, The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement., Baseline (Week 0) to Week 16|Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease., Baseline and Week 16|Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease., Baseline and Week 16|Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 4, The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement., Baseline (Week 0) to Week 4|Percentage of Participants Achieving a 75% Reduction From Baseline in EASI Score at Week 2, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease., Baseline and Week 2|Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 1, The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement., Baseline (Week 0) to Week 1|Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16, The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch)., Baseline and Week 16",,AbbVie,,ALL,"ADULT, OLDER_ADULT",PHASE3,692,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",M16-046|2018-002264-57,2019-02-21,2020-08-27,2020-12-09,2018-11-13,2022-01-10,2022-02-02,"Clinical Research Center AL /ID# 210277, Birmingham, Alabama, 35209-6802, United States|University of Arkansas for Medical Sciences /ID# 211688, Little Rock, Arkansas, 72205, United States|Tien Q Nguyen MD, Inc /ID# 208934, Fountain Valley, California, 92708-3701, United States|UCSF Fresno /ID# 213253, Fresno, California, 93701-2302, United States|Jonathan Corren, MD. INC /ID# 208987, Los Angeles, California, 90025-4749, United States|California Allergy and Asthma Medical Group /ID# 213680, Los Angeles, California, 90025-7014, United States|Dermatology Research Associates /ID# 209097, Los Angeles, California, 90045, United States|Los Angelos Cataract Center /ID# 208524, Los Angeles, California, 90056, United States|Dermatology Clinical Trials /ID# 214622, Newport Beach, California, 92660-7853, United States|UC Davis Health /ID# 209285, Sacramento, California, 95816, United States|Ucsd /Id# 208990, San Diego, California, 92103, United States|Clinical Science Institute /ID# 211022, Santa Monica, California, 90404-2102, United States|The Community Research of South Florida /ID# 211145, Hialeah, Florida, 33016-1897, United States|Miami Dermatology and Laser Institute /ID# 212938, Miami, Florida, 33173-3570, United States|Florida International Rsrch cr /ID# 211562, Miami, Florida, 33173, United States|Progressive Medical Research /ID# 211994, Port Orange, Florida, 32127, United States|GCP Research /ID# 216020, Saint Petersburg, Florida, 33705, United States|Clinical Research Trials of Florida, Inc. /ID# 210751, Tampa, Florida, 33607, United States|Integrated Clinical Research LLC /ID# 208831, West Palm Beach, Florida, 33406-6063, United States|Georgia Pollens Clinical Research Centers, Inc /ID# 211092, Albany, Georgia, 31707-1282, United States|Meridian Clinical Research Dermatology /ID# 213251, Savannah, Georgia, 31406-2632, United States|Northwestern University Feinberg School of Medicine /ID# 208680, Chicago, Illinois, 60611-2927, United States|Medical Dermatology Associates of Chicago /ID# 210265, Chicago, Illinois, 60654-6903, United States|Sneeze, Wheeze, & Itch Associates, LLC /ID# 212058, Normal, Illinois, 61761, United States|Dawes Fretzin, LLC /ID# 209187, Indianapolis, Indiana, 46256, United States|Beacon Clinical Research, LLC /ID# 209280, Quincy, Massachusetts, 02169, United States|Clarkston Skin Research /ID# 208739, Clarkston, Michigan, 48346, United States|Henry Ford Health System /ID# 208741, Detroit, Michigan, 48202, United States|Clinical Research Institute, Inc /ID# 210852, Minneapolis, Minnesota, 55402-2606, United States|Allergy, Asthma & Immunology Associates, PC /ID# 213481, Lincoln, Nebraska, 68505-2343, United States|Skin Specialists, PC /ID# 208843, Omaha, Nebraska, 68144, United States|Dartmouth-Hitchcock Medical Center /ID# 213727, Lebanon, New Hampshire, 03756, United States|Montefiore Medical Center /ID# 209647, Bronx, New York, 10467, United States|Forest Hills Dermatology Group /ID# 209249, Kew Gardens, New York, 11415, United States|Wake Forest Univ HS /ID# 208892, Winston-Salem, North Carolina, 27157, United States|Univ Hosp Cleveland /ID# 208852, Cleveland, Ohio, 44106, United States|The Ohio State University /ID# 209254, Columbus, Ohio, 43210-1257, United States|Southside Dermatology /ID# 212004, Tulsa, Oklahoma, 74132, United States|Oregon Medical Res Center PC /ID# 208807, Portland, Oregon, 97223, United States|Oregon Health and Science University /ID# 208809, Portland, Oregon, 97239, United States|Medical University of South Carolina /ID# 211054, Charleston, South Carolina, 29425, United States|Clinical Research Solutions, LLC /ID# 212542, Jackson, Tennessee, 38305-2163, United States|Orion Clinical Research /ID# 208765, Austin, Texas, 78759-4100, United States|DiscoveResearch, Inc. /ID# 213171, Bryan, Texas, 77802, United States|Epiphany Dermatology - Fort Worth /ID# 211187, Fort Worth, Texas, 76244-6548, United States|Sante Clinical Research /ID# 212970, Kerrville, Texas, 78028-9640, United States|Stephen Miller, MD PA /ID# 210071, San Antonio, Texas, 78249, United States|Sugar Land Allergy, Asthma, and Immunology Center /ID# 211153, Sugar Land, Texas, 77479-3153, United States|University of Utah /ID# 209001, Salt Lake City, Utah, 84112-5500, United States|Clinical Research Partners, LLC /ID# 212262, Richmond, Virginia, 23220-4459, United States|Premier Clinical Research /ID# 212142, Spokane, Washington, 99202, United States|West Virginia Research Inst /ID# 212730, South Charleston, West Virginia, 25309, United States|Holdsworth House Medical Practice /ID# 214565, Darlinghurst, New South Wales, 2010, Australia|The Skin Hospital /ID# 214401, Darlinghurst, New South Wales, 2010, Australia|Veracity Clinical Research /ID# 211134, Woolloongabba, Queensland, 4102, Australia|Sinclair Dermatology /ID# 209395, East Melbourne, Victoria, 3002, Australia|Burswood Dermatology /ID# 214875, Victoria Park, Western Australia, 6100, Australia|Kirk Barber Research, CA /ID# 209504, Calgary, Alberta, T2G 1B1, Canada|Dermatology Research Institute Inc. /ID# 210942, Calgary, Alberta, T2J 7E1, Canada|Dr. Chih-ho Hong Medical Inc. /ID# 211032, Surrey, British Columbia, V3R 6A7, Canada|Enverus Medical Research /ID# 209503, Surrey, British Columbia, V3V 0C6, Canada|Dr. Wei Jing Loo Medicine Prof /ID# 211400, London, Ontario, N6H 5L5, Canada|Lynderm Research Inc. /ID# 209505, Markham, Ontario, L3P 1X2, Canada|DermEdge Research Inc. /ID# 211122, Mississauga, Ontario, L5H 1G9, Canada|Niakosari Medicine Professional Corporation /ID# 211401, Toronto, Ontario, M2M 4J5, Canada|K. Papp Clinical Research /ID# 209509, Waterloo, Ontario, N2J 1C4, Canada|Dre Angelique Gagne-Henley M.D. inc. /ID# 209498, Saint-Jerome, Quebec, J7Z 7E2, Canada|DermaPlus - Poliklinika za dermatologiju i venerologiju /ID# 209935, Zagreb, Grad Zagreb, 10000, Croatia|Djecja bolnica Srebrnjak /ID# 209939, Zagreb, Grad Zagreb, 10000, Croatia|Klinicki bolnicki centar Zagreb /ID# 209976, Zagreb, Grad Zagreb, 10000, Croatia|Naftalan - Specijalna bolnica za medicinsku rehabilitaciju /ID# 209937, Ivanic-Grad, Zagrebacka Zupanija, 10310, Croatia|Fakultni Nemocnice Brno /ID# 212968, Brno, 625 00, Czechia|FN Hradec Kralove /ID# 209116, Hradec Kralove, 500 05, Czechia|Nemocnice Jihlava, prispevkova organizace /ID# 209131, Jihlava, 586 01, Czechia|Fakultni nemocnice Ostrava /ID# 209117, Ostrava, 708 52, Czechia|Fakultni Nemocnice v Motole /ID# 209209, Praha, 150 06, Czechia|Keski-pohjanmaa Central Hospital /ID# 209534, Kokkola, Keski-Pohjanmaa, 67200, Finland|Oulu University Hospital /ID# 208961, Oulu, Pohjois-Pohjanmaa, 90220, Finland|Mikkeli Central Hospital /ID# 210125, Mikkeli, 50100, Finland|Pihlajalinna Turku /ID# 209599, Turku, 20100, Finland|CHRU Lille - Hopital Claude Huriez /ID# 209317, Lille CEDEX, Hauts-de-France, 59045, France|CHU de Nantes - Hotel Dieu /ID# 208974, Nantes CEDEX 1, Pays-de-la-Loire, 44093, France|Charles Nicolle CHU Rouen /ID# 208973, Rouen CEDEX, Seine-Maritime, 76031, France|Hopital de la Timone /ID# 211245, Marseille, 13385, France|Centre Hospitalier Universitaire de Nice - Hopital l'Archet 2 /ID# 213374, Nice, 06202, France|Polyclinique Courlancy /ID# 208975, Reims, 51100, France|Hopital Larrey - CHU de Toulouse /ID# 208976, Toulouse, 31059, France|Universitatsklinikum Munster /ID# 210935, Munster, Niedersachsen, 48149, Germany|Gemeinschaftspraxis /ID# 211174, Blankenfeld-mahlow, 15831, Germany|Hautklinik Klinikum Darmstadt /ID# 210938, Darmstadt, 64283, Germany|Universitaetsklinikum Frankfurt /ID# 210934, Frankfurt, 60590, Germany|Medizinische Hochschule Hannover /ID# 210939, Hannover, 30625, Germany|TU Uniklinik Munchen /ID# 210937, Munich, 80802, Germany|Oroshazi Korhaz /ID# 210150, Oroshaza, Bekes, 5900, Hungary|Uno Medical Trials Kft /ID# 211177, Budapest XIII, 1135, Hungary|Debreceni Egyetem Klinikai Kozpont /ID# 210893, Debrecen, 4032, Hungary|Somogy Megyei Kaposi Mor Oktat /ID# 210149, Kaposvar, 7400, Hungary|Pecsi Tudomanyegyetem Klinikai l.sz. Belgyogyaszati Klinika /ID# 210892, Pecs, 7624, Hungary|St Vincent's University Hosp /ID# 208441, Dublin, D04 T6F4, Ireland|University Hospital Waterford /ID# 208442, Waterford, X91 ER8E, Ireland|HaEmek Medical Center /ID# 210153, Afula, 1834111, Israel|Rabin Medical Center /ID# 210012, Petakh Tikva, 4941492, Israel|Sheba Medical Center /ID# 210013, Ramat Gan, 5239424, Israel|Ichilov Medical Center /ID# 210014, Tel Aviv, 64239, Israel|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 210632, Milan, Lombardia, 20122, Italy|IBD Center - IRCCS Istituto Clinico Humanitas /ID# 215726, Rozzano, Milano, 20089, Italy|A.O. Policlinico Sant'Orsola Malpighi /ID# 209111, Bologna, 40138, Italy|A.O.U. di Brescia /ID# 209115, Brescia, 25123, Italy|Ospedale San Giovanni di Dio /ID# 209109, Cagliari, 9124, Italy|AO Univ di Modena /ID# 209110, Modena, 41100, Italy|Policlinico Univ Tor Vergata /ID# 209112, Rome, 00133, Italy|Hospital Sultan Ismail /ID# 211037, Johor Bahru, Johor, 81100, Malaysia|Hospital Pakar Sultanah Fatimah /ID# 210185, Muar, Johor, 84000, Malaysia|UKM Medical Centre /ID# 209178, Kuala Lumpur, Selangor, 56000, Malaysia|University Malaya Med Ctr /ID# 208861, Kuala Lumpur, 59100, Malaysia|Hospital Pulau Pinang /ID# 210212, Penang, 10450, Malaysia|Hospital Putrajaya /ID# 209177, Putrajaya, 62250, Malaysia|Bravis Ziekenhuis /ID# 208584, Bergen op Zoom, Noord-Brabant, 4624 VT, Netherlands|Academisch Medisch Centrum /ID# 208578, Amsterdam, Noord-Holland, 1105 AZ, Netherlands|Centrum Oosterwal /ID# 209641, Alkmaar, 1817 MS, Netherlands|Universitair Medisch Centrum Groningen /ID# 208583, Groningen, 9713 GZ, Netherlands|Erasmus Medisch Centrum /ID# 208582, Rotterdam, 3015 GD, Netherlands|Universitair Medisch Centrum Utrecht /ID# 208579, Utrecht, 3584 CX, Netherlands|Optimal Clinical Trials Ltd /ID# 209475, Auckland, 1010, New Zealand|Clinical Trials NZ /ID# 215590, Hamilton, 3206, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 215001, Wellington, 6021, New Zealand|St. Olavs Hospital HF /ID# 209137, Trondheim, Sor-Trondelag, 7006, Norway|Universitetssykehuset N-Norge, Harstad /ID# 209105, Harstad, Troms, 9406, Norway|Universitetssykehuset N-Norge, Tromso /ID# 209103, Tromso, Troms, 9019, Norway|Szpital Uniwersytecki nr 1 im. dr. A. Jurasza w Bydgoszczy /ID# 211103, Bydgoszcz, Kujawsko-pomorskie, 85-094, Poland|Dermoklinika Medical Center /ID# 211026, Lodz, Lodzkie, 90-436, Poland|Pratia MCM Krakow /ID# 207444, Krakow, Malopolskie, 30-510, Poland|Klinika Ambroziak Sp. z o.o. /ID# 207443, Warsaw, Mazowieckie, 02-758, Poland|Royalderm Agnieszka Nawrocka /ID# 211015, Warszawa, Mazowieckie, 02-962, Poland|ClinicMed Daniluk, Nowak Sp.j. /ID# 211112, Bialystok, Podlaskie, 15-879, Poland|National Skin Centre /ID# 208775, Singapore, Central Singapore, 308205, Singapore|National University Hospital /ID# 208774, Singapore, 119074, Singapore|Singapore General Hospital /ID# 208776, Singapore, 169608, Singapore|Hospital Universitario de Bellvitge /ID# 207063, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital Universitario Dr. Negrin /ID# 208969, Las Palmas de Gran Canaria, Las Palmas, 35010, Spain|Hospital de Manises /ID# 207062, Manises, Valencia, 46940, Spain|Complejo Hospitalario Universitario de Pontevedra /ID# 207139, Pontevedra, 36071, Spain|Hospital Universitario Arnau Vilanova /ID# 207065, Valencia, 46015, Spain|Hospital Universitario y Politecnico La Fe /ID# 207064, Valencia, 46026, Spain|Skanes Universitetssjukhus /ID# 206783, Malmö, Skane Lan, 214 28, Sweden|Karolinska University Hospital /ID# 207909, Stockholm, SE-17176, Sweden|China Medical University Hosp /ID# 209770, Taichung City, Taichung, 40447, Taiwan|National Taiwan University Hospital /ID# 208309, Taipei City, Taipei, 100, Taiwan|Chung Shan Medical University /ID# 208311, Taichung City, 40201, Taiwan|Taipei Municipal Wan Fang Hospital /ID# 209987, Taipei, 116, Taiwan|Military Hospital of Military-Medical Clinical Center of Southern Region /ID# 210435, Zaporizhzhya, Zaporizka Oblast, 69063, Ukraine|Kyiv City Clinical Skin and Venereal Hospital /ID# 210755, Kyiv, 04209, Ukraine|ME ""Rivne Regional Dermatology and Venereology Dispensary"" of RRC /ID# 210434, Rivne, 33028, Ukraine|Royal Alex Childrens County Hospital /ID# 209709, Brighton, Brighton And Hove, BN2 5BE, United Kingdom|Victoria Hospital /ID# 209853, Kirkcaldy, Fife, KY2 5AH, United Kingdom|Royal Hospital for Children /ID# 210451, Glasgow, Glasgow City, G51 4TF, United Kingdom|The Royal Free Hospital /ID# 208659, London, London, City Of, NW3 2QG, United Kingdom|Guy's and St Thomas' NHS Found /ID# 208881, London, London, City Of, SE1 9RT, United Kingdom|Cardiff & Vale University Health Board /ID# 209745, Cardiff, Wales, CF14 4XN, United Kingdom","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/97/NCT03738397/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/97/NCT03738397/SAP_001.pdf"
